AI drug discovery startup Isomorphic Labs enters fundraising talks with a valuation of at least $40 billion

Isomorphic Labs, an AI drug discovery company under Alphabet and led by Demis Hassabis, is in early-stage negotiations for a new round of financing, with a valuation of at least $40 billion and potentially reaching $50 billion. The company previously closed a $2.1 billion Series B funding round in May this year. Reports also indicate that the application of AI in the biopharmaceutical sector remains in its early stages, and more work is still needed before clinical trials and product launches can take place. These talks are still preliminary, with specific terms and investor details undisclosed.